The significant beat on earnings estimates and the year-over-year revenue increase are strong indicators of Capricor Therapeutics' financial health and operational success. Historically, such positive earnings reports have led to an increase in share price, as evidenced by the 7% increase following last quarter's earnings beat. This pattern suggests a likely positive short-term impact on CAPR's stock price.